NEW YORK (GenomeWeb News) – A shareholder is suing Sequenom and its board, alleging they breached their fiduciary duty and damaged the company by implementing an illegal strategy to drive up orders of the MaterniT21 Plus non-invasive prenatal diagnostic test.

The lawsuit was filed on Sept. 30 in the US District Court for the Southern District of California by Bette Borenstein derivatively on behalf of Sequenom, who also is a nominal defendant.

Through a spokesperson, Sequenom said that it does not comment on ongoing legal actions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.